Skip to content
Top Globe News – Lifestyle
Author:
Compass Therapeutics
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
May 21, 2026
Compass Therapeutics to Participate in Upcoming May Investor Events
May 12, 2026
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
May 5, 2026
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
April 29, 2026
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
April 29, 2026